Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Veerhealth CareBOM:511523 +0.33%65 Days Payable is 78.34 as of Mar. 2026, which is 39% above its 10-year median of 56.31. GuruFocus rates BOM:511523 with a GF Score™ of 65/100 and a GF Value™ of ₹41.45 (Fairly Valued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Veerhealth Care ranks worse than 50.81% on this metric.
The historical data trend for Veerhealth Care's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Veerhealth Care's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veerhealth Care Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Veerhealth Care's Days Payable distribution charts can be found below:
* The bar in red indicates where Veerhealth Care's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Veerhealth Care's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veerhealth Care (BOM:511523) has a Days Payable of 78.34 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veerhealth Care and its competitors. This is 39% above median its historical median of 56.31. Over the past decade, Veerhealth Care's Days Payable has ranged from 20.05 to 111.42. According to the industry distribution chart, Veerhealth Care ranks #471 out of 927 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Veerhealth Care's Days Payable too high?
Veerhealth Care's current Days Payable of 78.34 is 39% above median its 10-year median of 56.31. Over the past 10 years, this metric has ranged from a low of 20.05 to a high of 111.42. The Drug Manufacturers industry median Days Payable is 90.28. Veerhealth Care's value of 78.34 is 13.2% below this industry median. Based on the distribution chart, Veerhealth Care ranks #471 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Veerhealth Care has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Veerhealth Care's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Veerhealth Care ranks #471 out of 927 companies for Days Payable. This places Veerhealth Care in the lower half of its industry. The industry median Days Payable is 90.28. Veerhealth Care's value of 78.34 is 13.2% below this benchmark. Historically, Veerhealth Care's own Days Payable has ranged from 20.05 to 111.42 over the past decade. While the company's 10-year median is 56.31 vs. the industry median of 90.28, Veerhealth Care has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.28, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veerhealth Care's current Days Payable of 78.34 is 13.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Veerhealth Care and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veerhealth Care's current Days Payable is 78.34, which is 39% above median its own 10-year median of 56.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veerhealth Care stock overvalued right now?
Based on GuruFocus' analysis, Veerhealth Care (BOM:511523) is currently considered Fairly Valued. The stock's GF Value™ is ₹41.45, compared to a current price of ₹42.20 — trading 1.8% above its estimated fair value. The current Days Payable is 78.34, which is 39% above median its 10-year median of 56.31 and 13.2% below the Drug Manufacturers industry median of 90.28. Veerhealth Care's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Veerhealth Care (BOM:511523), the current Days Payable is 78.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veerhealth Care (BOM:511523) Overvalued in 2026?
Based on GuruFocus' analysis, Veerhealth Care stock appears to be overvalued.
The current stock price of ₹42.20 is trading 1.8% above its estimated GF Value™ of ₹41.45.
GuruFocus considers Veerhealth Care to be Fairly Valued.
Key valuation signals for BOM:511523:
Days Payable: 78.34 (39% above median its 10-year median of 56.31)
GF Value™: ₹41.45 vs. price of ₹42.20 (1.8% above fair value)
Industry Position: 13.2% below the Drug Manufacturers median (#471 of 927)
No single metric tells the full story. See the BOM:511523 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veerhealth Care Ltd is an India-based pharmaceutical company. It is engaged in the business of trading and manufacturing and marketing research-based Ayurvedic medicines. It operates in a single segment namely Ayurved Pharma Products.
65GF Score
Get the complete analysis for BOM:511523
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:511523 has been successfully added to your 
